-
1.发明申请
公开(公告)号：WO2023092089A1
公开(公告)日：2023-05-25
申请号：PCT/US2022/080167
申请日：2022-11-18
Inventor： KIM, HoWon J. , KIM, In-San , KIM, Jay S. , KIM, Sun Hwa , KWON, Ick Chan , LEE, Jong Won , YANG, Yoo Soo , YOON, Hong Yeol
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.
-
2.发明申请
公开(公告)号：WO2022196865A1
公开(公告)日：2022-09-22
申请号：PCT/KR2021/006868
申请日：2021-06-02
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , MOKPO NATIONAL UNIVERSITY INDUSTRY-ACADEMIA COOPERATION GROUP
Inventor： KIM, In-San , PARK, Jin Woo , NAM, Gi-hoon , KIM, Seong A , BAE, Youngrang
IPC: A61K9/107 , A61K9/00 , A61K47/28 , A61K47/18 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/4412 , A61K31/47 , A61K45/06
Abstract: Provided are a lipophilic statin composition with improved solubility and permeability and uses thereof. The simvastatin (SIMVA)/DL-colloidal dispersion (CD) composite according to the present invention may be applied to effective anticancer immunotherapy.
-
3.发明申请ANTICANCER DRUG-CHITOSAN COMPLEX FORMING SELF-AGGREGATES AND PREPARATION METHOD THEREOF 审中-公开抗生素药物复合物形成自聚集体及其制备方法
公开(公告)号：WO2003015827A1
公开(公告)日：2003-02-27
申请号：PCT/KR2002/001554
申请日：2002-08-14
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , JAKWANG CO., LTD. , KWON, Ick,Chan , KIM, In-San , JEONG, Seo,Young , CHUNG, Hesson , CHO, Yong,Woo , SON, Yoen,Ju , PARK, Chong,Rae , SEO, Sang, Bong
Inventor： KWON, Ick,Chan , KIM, In-San , JEONG, Seo,Young , CHUNG, Hesson , CHO, Yong,Woo , SON, Yoen,Ju , PARK, Chong,Rae , SEO, Sang, Bong
IPC: A61K47/48
CPC classification number: A61K31/704 , A61K47/61 , A61K47/6907
Abstract: The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.
Abstract translation: 本发明涉及形成自聚集体的抗癌药物 - 壳聚糖复合物及其制备方法。 更准确地说，本发明涉及在由疏水性抗癌剂和亲水性壳聚糖组成的水性介质中形成自聚集体的抗癌药物 - 壳聚糖复合物及其制备方法。 本发明的抗癌药物 - 壳聚糖复合物不仅对目标肿瘤组织有选择性的作用，而且还能够长时间地释放药物。 此外，抗癌药物 - 壳聚糖复合物可以通过将抗癌药物加入自聚集体中而具有更大量的药物，其通常受化学键的限制。 因此，本发明的抗癌药物 - 壳聚糖复合物可以有效地用于癌症化疗。
-
公开(公告)号：EP3345929A1
公开(公告)日：2018-07-11
申请号：EP16842349.9
申请日：2016-09-02
Applicant: Kyungpook National University Industry-Academic Cooperation Foundation , Korea Institute of Science and Technology
Inventor： BAE, Jong-Sup , KIM, In-San , LEE, Won Hwa , SEO, Jun Young , KIM, So Youn
CPC classification number: A61K38/16 , A61K38/17 , C07K14/47 , C07K14/54 , C07K14/79 , C07K19/00 , Y02A50/40
Abstract: The present invention relates to: a fusion polypeptide in which an anti-inflammatory polypeptide and a ferritin monomer fragment are bound; and a pharmaceutical composition for treating inflammatory diseases, containing the same as an active ingredient and, more specifically, to: a fusion polypeptide in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a ferritin monomer fragment from which a portion of a fourth loop and a fifth helix, of a human derived ferritin monomer, are removed; and a use thereof for treating inflammatory diseases. As in the above, the fusion polypeptide, which has an amino acid sequence represented by SEQ ID NO: 1 and in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a fragment of a human-derived ferritin monomer, can fuse two types of anti-inflammatory polypeptides, acting through different mechanisms, into a nano cage and administer the same, and thus the fusion polypeptide can exhibit an excellent effect in the treatment of inflammatory diseases including sepsis.
-
公开(公告)号：EP4252743A1
公开(公告)日：2023-10-04
申请号：EP21898239.5
申请日：2021-04-29
Applicant: Korea Institute of Science and Technology
Inventor： KIM, In-San , KIM, Gi-beom , NAM, Gi-hoon , KIM, Seonghyun , YANG, Yoosoo
Abstract: Provided are an exosome expressing a respiratory syncytial virus F protein (RSVF) and use thereof.
The exosome expressing the respiratory syncytial virus F protein (RSVF) according to the present invention kills cancer cells by specifically fusing to membranes of cancer cells, and suppresses tumor growth by accumulating in a tumor specific manner, and accordingly, it may be used in the prevention or treatment of cancer.-
Patent Agency Ranking
公开(公告)号：EP4197559A1
公开(公告)日：2023-06-21
申请号：EP20949578.7
申请日：2020-08-14
Applicant: Korea Institute of Science and Technology
Inventor： KIM, Sun Hwa , KWON, Ick Chan , KIM, In-San , KIM, Kwangmeyung , YANG, Yoosoo , KO, Young-ji
IPC: A61K47/64 , A61K47/65 , A61K31/713 , A61P35/00 , C12N15/115
Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.
-
公开(公告)号：EP3563835A1
公开(公告)日：2019-11-06
申请号：EP17888530.7
申请日：2017-12-29
Applicant: Korea Institute of Science and Technology
Inventor： KOH, Eun-ee , LEE, Eun Jung , YANG, Yoo Soo , KIM, In-San
IPC: A61K9/127 , A61K47/69 , A61K47/68 , A61K31/519 , A61K31/505 , A61K31/69 , A61K31/704 , A61K45/06 , C07K14/47
Abstract: The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention privides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface thereof.
-
8.发明公开
公开(公告)号：EP4340893A1
公开(公告)日：2024-03-27
申请号：EP22844608.4
申请日：2022-11-18
Inventor： KIM, HoWon J. , KIM, In-San , KIM, Jay S. , KIM, Sun Hwa , KWON, Ick Chan , LEE, Jong Won , YANG, Yoo Soo , YOON, Hong Yeol
-
9.发明授权ANTICANCER DRUG-CHITOSAN COMPLEX FORMING SELF-AGGREGATES AND PREPARATION METHOD THEREOF 有权壳聚糖复为AUTO单位用于制造癌症治疗的成因及过程
公开(公告)号：EP1383539B1
公开(公告)日：2006-07-26
申请号：EP02758920.9
申请日：2002-08-14
Inventor： KWON, Ick Chan , KIM, In-San , JEONG, Seo Young , CHUNG, Hesson , CHO, Yong Woo , SON, Yoen Ju, 106-1404 Sinkongduk samsung Apt. , PARK, Chong Rae, Ga-102 Seoul Univ. kyosu Apt. , SEO, Sang, Bong
IPC: A61P35/00
CPC classification number: A61K31/704 , A61K47/61 , A61K47/6907
Abstract: The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.
-
公开(公告)号：EP3501509A1
公开(公告)日：2019-06-26
申请号：EP17828021.0
申请日：2017-07-17
Applicant: Korea Institute of Science and Technology
Inventor： NAM, Gi Hoon , LEE, Eun Jung , YANG, Yoo Soo , JEONG, Cherl Hyun , KIM, In-San , KIM, Kwangmeyung
IPC: A61K9/51 , C07K14/47 , C07K14/79 , A61K39/395 , A61K31/69 , A61K31/704
Abstract: The present invention relates to a novel recombinant nanocage and use thereof. More particularly, the present invention relates to a nanocage formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and a protein nanocage complex in which an immunogenic cell death inducer loaded in the nanocage as an active ingredient.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.035 seconds)
